GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system

GE HealthCare announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system, a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative system represents a leap forward in molecular imaging capabilities and clinical efficiency.

As global cancer rates continue to rise – projected to increase 77 percent by 2050 – the need for advanced imaging solutions has never been greater. The growing prevalence of cancer and emergence of investigational immunotherapies and targeted treatments have accelerated the demand for whole-body PET/CT imaging. GE HealthCare’s new technology is built to meet this need, supporting theranostics and enabling clinicians to visualize, diagnose and monitor disease with impressive precision and speed.

“Our commitment to precision health is rooted in innovation that also aims to anticipate the future of care,” says Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “With our Omni 128cm total body PET/CT system, we’re not just advancing imaging – we’re building a platform that empowers clinicians to deliver personalized, efficient and impactful care. The system also supports researchers in developing new clinical pathways. This milestone underscores our vision of enabling clinicians to achieve better outcomes through smarter, scalable solutions.”

“PET/CT has transformed our ability to visualize disease at the cellular level, offering insights that were once out of reach,” shares Prof. Michael Hofman, nuclear medicine physician and head of the PET/CT program at Melbourne’s Peter MacCallum Cancer Centre. “With the Omni 128cm total body PET/CT system, we’re entering a new phase of possibility – one where faster scans and broader imaging coverage could redefine how we approach translational research and accelerate the development of targeted therapies.”

“This next-generation PET/CT technology is engineered to deliver exceptional sensitivity and resolution – capabilities that could reshape how we approach molecular imaging,” adds Dr. Ken Herrmann,  director and chairman, Department of Nuclear Medicine, Universitätsklinikum Essen. “Its speed and precision open the door to new possibilities, from helping reduce the need for anesthesia in pediatric scans to enabling multi organ dynamic imaging and early, confident diagnoses. It’s a powerful tool for advancing both research and patient care.”